Renal transplant patients of the Northern Territory (NT) of Australia, suffer poor transplant outcomes including graft rejection, infection and increased mortality, therefore requiring stringent immunosuppressive drug assay monitoring. Best practice dictates that drug assay results should be received within 24 hours and at the most no later than 48 hours post blood collection. Assays from the Royal Darwin Hospital (RDH) are processed at an interstate laboratory, therefore prolonging the time to dosage adjustment.
ABSTRACT Background
Renal transplant patients of the Northern Territory (NT) of Australia, suffer poor transplant outcomes including graft rejection, infection and increased mortality, therefore requiring stringent immunosuppressive drug assay monitoring. Best practice dictates that drug assay results should be received within 24 hours and at the most no later than 48 hours post blood collection. Assays from the Royal Darwin Hospital (RDH) are processed at an interstate laboratory, therefore prolonging the time to dosage adjustment.
Aims
To assess the time delay that exists between blood sample collection at the Royal Darwin Hospital (RDH) and the faxing of results from an interstate laboratory to RDH. 
Methods

Conclusion
The long median time delay between sample collection and receiving of results illustrates the challenges of immunosuppression in this setting and the need for on-site immunosuppressive drug assaying.
Background
The Northern Territory (NT) bears much of the brunt of Chronic Kidney Disease (CKD) in Australia. Among its Indigenous population, CKD is 4-10 times higher when compared to non-Indigenous Australians. This is principally attributed to higher rates of diabetes mellitus, hypertension, smoking, infections, glomerular disease and low nephron endowment. Renal replacement treatments (RRT) including peritoneal dialysis, home haemodialysis and community health centre dialysis, is offered, thus diminishing the need to relocate to greater centres for treatment for those who can use these modalities of treatment. Unfortunately, however, due to the many challenges of living remotely and the large burden of co-morbidities among Indigenous people, these alternatives are offered to a minority of patients. This therefore leaves most patients accepting haemodialysis in bigger centres in Darwin, Katherine and Alice Springs, often at the cost of being separated from their homeland, cultural responsibilities, children and spouses.
In a bid to improve both patient outcomes, there has been a recent increase in the number of successful renal transplantation in the NT. Unpublished data suggests that over the last 6 years renal transplants have almost doubled, therefore increasing the use of services involved in routine transplant care.
Renal transplantation among most patients with end stage renal failure (ESRF) is the most effective form of renal replacement therapy. It offers improved quality of life, reduced morbidity, mortality and economic benefits in most patient populations when compared to dialysis. [3] [4] [5] [6] Specifically, renal transplantation compared to haemodialysis, is associated with improved patient survival 3 . However, when paralleled to non-Indigenous transplant patients, Indigenous renal transplant recipients suffer higher rates of renal allograft loss and mortality. [4] [5] [6] Data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry published by McDonald et al. in 2004, analysed both graft survival and patient survival at 5 years post transplantation, between Indigenous and Non Indigenous patients. At 5 years post transplantation, graft survival of Indigenous transplant recipients was 47.8 per cent compared to 80 per cent in non-Indigenous recipients. Similarly, at 5 years post transplantation, patient survival among Indigenous patients was 61.7 per cent compared to 88.7 per cent among non-Indigenous patients. 5 Various factors such as increased rates of infection, septicaemia, increased plasma cell infiltrates in grafts (thus increasing susceptibility to post transplant infection rates due to increased immunosuppression burden). Greater rates of human leukocyte antigen (HLA) mismatches and increased rate of sensitisation prior to transplant among Indigenous recipients with increased rates of rejection, were attributed to the disparities. 1, 4, 5 Additionally, poor outcomes in the NT were also attributed to the absence of on-sight renal pathologists and of specific interest to this report, the absence of on-site immunosuppressive drug assay processing. 7, 4 At RDH, immunosuppressive drug assays from patients are currently done in interstate laboratories. Patient blood samples are collected by pathology at RDH prior to morning dose administration. Multiple samples are then sent collectively to an interstate laboratory by aeroplane for analysis. Once reported at the interstate laboratory, these reports are finally faxed back to RDH, for clinicians to review.
Often drug assay results take a considerable amount of time to return. In some instances local clinicians report reviewing patients in transplant clinics 2-3 days post blood sampling, without being able to comment on dosage regimes due to pending drugs assay results. Best practice dictates that immunosuppressive drug assays should be received within 24 hours and no later than 48 hours post blood collection, for the optimum management of renal transplant care.
This audit aimed to assess the time delay that exists between blood sample collection at RDH, drug assay reporting and the faxing of results from an interstate laboratory back to RDH. A renal transplant patient information database and medical files were used to extract immunosuppressive drug assay results and demographic data.
Method
The following de-identified data was extracted; the dates and times blood samples were collected at RDH, the dates and times blood drug assays were reported at an interstate laboratory, the dates and times drug assay reports were faxed back to RDH and finally drug assays whose reports were signed by doctors noting the need for dosage changes. This audit is the first study assessing the challenges of lacking on-site immunosuppressive assay monitoring, in a remote-regional centre in Northern Australia. The results suggest that a greater than 48 hours median time delay exists. A total time from blood sample collection to receiving of faxed results of 53.48 hours has significant implications for outcomes particularly for those requiring treatment of rejection, requiring change of dose or those developing graft dysfunction. The decision to manage these patients will largely end up being empirical whilst waiting for the results, which is not best practice. The data further demonstrated many of these hours (47.18 hours), to be occupied by the hours between blood sample collection in Darwin, sending of samples and results reporting at an interstate laboratory. Conversely, the hours between results reporting at the interstate laboratory and the faxing of results to Darwin was very short, (2.7 hours) demonstrating the possibility of receiving results within 2 to 4 hours if onsite analysis was established. These results indicate that time is lost in the collection of samples in Darwin, the sending of sample and reporting at an interstate laboratory, and thus provide strong justification for on-sight monitoring. A significant number of changes to collection and transport of samples have already been implemented following the presentation of these results, with the eventual aim of setting up an on-site process for analysis.
Among the 13.3 per cent of drug assays that did require dosage changes, time delays were not statically different from those that did require changes. These results suggest there is a problem across all practice regardless of the urgency of results. Patients and their clinicians waited long times before being able to change to the appropriate and safe immunosuppressive doses, which could have compromised their grafts and outcomes.
Published literature states that immunosuppressive drug assaying is an essential tool in the achievement of the optimum balance between therapeutic effects versus adverse reactions. 7 Pharmacological agents such as tacrolimus, sirolimus, Everolimus, cyclosporine and mycophenolate may exhibit a high degree of ethnic pharmacodynamics and pharmacokinetic variability. 8, 9 As these are the drugs used in our transplant patients, it is prudent that the monitoring of their levels occurs in a timely manner.
There are some limitations in this study that should be acknowledged. The main limitation being that time was not correlated to renal function. This would have allowed greater insight into the consequences of delayed dosage changes. However, the aim of this study was to assess the deviation from the time limits for getting the results back and within this limitation the study showed significant findings. The study did not differentiate between new transplant and old transplant recipients, where patients with new transplants are at a time of high risk. Additionally, due to the limited data availability to researchers, total time was only analysed in the three intervals, where some intervals involved multiple steps. Finally, a cost benefit analysis comparing the assaying of samples interstate versus the assaying of samples locally at RDH was not conducted.
Among the 389 immunosuppressive drug assays audited, a greater than 48 hours median delay exists. The greatest delay in time lies in the sending of samples and the processing drug assays at an interstate laboratory.
Recommendations from this audit have led to a process of improving blood sample collection and transport to the interstate laboratory whilst a more robust system of on-site monitoring is developed. Further work needs to be done to assess the effect of time delays on graft function, infection episodes, patient outcomes and long term survival of both the renal transplants and the patients.
Conclusion
In order to improve the management of transplant patients this audit supports the commencement of on-site drug assay analysis in the Top End of the Northern Territory. 
